Business Wire

DE-CSC

3.9.2024 15:01:35 CEST | Business Wire | Press release

Share
Project Finance Use to Surge Over the Next Two Years

An overwhelming majority (86%) of industry experts believe project finance as a method of financing large scale infrastructure projects will grow in use over the next two years. This is according to a major new global study1 commissioned by CSC, the world’s leading provider of global business administration and compliance solutions.

North America, benefitting from the Inflation Reduction Act (IRA) among other tailwinds, is predicted to see the most significant uptick in project finance activity over the next two years, selected by over a third (39%) of respondents.

On a sectoral level, renewable energy projects such as wind and solar are seeing the most activity, representing the primary focus area for over half (55%) of respondents. This is followed by infrastructure, including roads, bridges and airports (29%). Within renewables, solar is expected to see the biggest increase in deals over the next 24 months.

CSC’s Project Finance Report 2024 focuses on the outlook for project finance deal activity across regions and sectors globally. The findings are based on the views of industry professionals working in project finance across North America, Europe, the U.K., Latin America, and Asia Pacific (APAC), in industries including banking and finance, development and construction, power and energy.

Corresponding with these findings, CSC has anecdotally observed a recent increase in project finance related deal flow.

“We're seeing renewed momentum for project finance deals across various markets as pandemic-related obstacles recede and supportive regulatory changes and legislation take root,” says Bryan Gartenberg, managing director at CSC. “Growing urgency to invest in renewable energy infrastructure coupled with global demographic shifts and rising prosperity are all driving demand for project finance, giving rise to new opportunities and challenges for market participants.”

Regional growth

While deal growth is expected in all surveyed regions, North America is predicted to be the most dynamic. This is, in part, due to the IRA, though Export Credit Agencies (ECAs) are also seen as being central to driving sponsorship of project finance structures and attracting institutional investors.

North America is followed by Latin America, Europe—which is enjoying supportive regulation in the form of European Long-Term Investment Funds (ELTIF 2.0)—and the U.K., with 29% of those surveyed expecting each of these regions to see an increase in activity.

In line with the report’s findings, CSC has observed conditions for growth in the Latin American market.

“While Latin America is slightly behind globally when it comes to the investment in the infrastructure and energy sectors, investment in the sector is a key objective for many of the regions’ administrations, and will fuel economic and GDP growth,” says Michael Morcom, managing director, Latin America at CSC. “Countries such as Brazil have introduced new regulations for infrastructure debentures and have allowed power purchase agreements (PPAs) to be denominated in U.S. dollars with the goal of attracting more foreign investment, and we’re seeing stirrings in other markets such as Colombia, Argentina, and Peru, following a few years of under-investment.”

APAC, meanwhile, was cited by just over a quarter (26%) of those surveyed.

“APAC is increasingly active in project financing, particularly in Australia where there is a strong commitment to net zero, and in Japan, which is exporting capital through its large banks to projects in the APAC region,” says Con Kleanthous, managing director, APAC at CSC.

Sector growth

The top four industries respondents are currently focused on are renewable energy projects (cited by 55% of respondents); infrastructure (29%); oil and gas (25%); and real estate development (24%).

Within the renewable energy project space, respondents believe solar will see the biggest increase in deals over the next two years, followed by wind (24%), fuel cell (14%), and green hydrogen (12%).

“Wind and solar are at the forefront because of their proven track record on bankability, but as emerging technologies are proven to be successful from a financing perspective, we can expect to see more growth in newer asset classes like hydrogen. This is, in turn, engendering ever-complex project finance structures needed to accommodate them,” says Gartenberg.

“As these structures grow in complexity, it’s increasingly important to ensure that all parties involved have the right levels of experience and knowledge—particularly when a project goes across multiple countries and local financial and regulatory expertise is needed,” continues Gartenberg. “Engaging a trust and agency service provider with a robust understanding of local markets, a strong track record, and the ability to take on various roles—including that of collateral agent, account bank, administrative agent, and inter-creditor agent—can thus play a key role in minimizing risks and ensuring that a deal runs smoothly and protects stakeholders’ interests.”

To receive a copy of CSC’s Project Finance Report 2024 report, please contact Camilla Wyatt or Lucy Gibbs at cscteam@citigatedewerogerson.com.

Notes to editors

1 CSC, in partnership with Pure Profile, surveyed 200 industry professionals working in project finance to understand their views on which regions are currently seeing the greatest activity for project finance deals, and how this will change in the near future. Respondents were split across North America, Europe, the UK, Latin America, and Asia Pacific, and worked across different industries, including banking and finance, construction, and energy.

About CSC

CSC is the trusted partner of choice for more than 90% of the Fortune 500®, more than 90% of the 100 Best Global Brands (Interbrand®), and more than 70% of the PEI 300. We are the world’s leading provider of global business administration and compliance solutions, specialized administration services to alternative asset managers across a range of fund strategies, transactions involving capital markets participants in both public and private markets, domain name system management and digital brand and fraud protection, and corporate tax software solutions. Founded in 1899 and headquartered in Wilmington, Delaware, USA, CSC prides itself on being privately held and professionally managed for more than 125 years. CSC has office locations and capabilities in more than 140 jurisdictions across Europe, the Americas, Asia Pacific, and the Middle East. We are a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. We are the business behind business®. Learn more at cscglobal.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240903259861/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye